Evidence map›Paper›PMID 33165727›Full record

ArticleFamilial cancer2021

Age at diagnosis of cancer in 185delAG BRCA1 mutation carriers of diverse ethnicities: tentative evidence for modifier factors.

Yael Laitman, Rachel Michaelson-Cohen, Rakefet Chen-Shtoyerman, Yael Goldberg, Orit Reish, Rinat Bernstein-Molho, Ephrat Levy-Lahad, Noa Ephrat Ben Baruch, Inbal Kedar, D Gareth Evans and 3 more

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Familial cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 2 countries.

Yael LaitmanThe Oncogenetics Unit, Institute of Human Genetics, and the Meirav High Risk Clinic, Chaim Sheba Medical Center, Tel-Hashomer, Israel.
Rachel Michaelson-CohenThe Medical Genetics Institute and the NOGA High Risk Clinic, Shaare Zedek Medical Center, Affiliated with the Hebrew University School of Medicine, Jerusalem, Israel.
Rakefet Chen-ShtoyermanThe Oncogenetics Clinic, The Clinical Genetics Institute, Kaplan Medical Center, Rehovot, Affiliated with the Hebrew University School of Medicine, Jerusalem, Israel.
Yael GoldbergRabin Medical Center, Recanati Genetics Institute, Belinson Hospital, 4941492, Petah Tikvah, Israel.
Orit ReishGenetics Institute, Shamir Medical Center, Zerifin, Affiliated to The Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Rinat Bernstein-MolhoThe Oncogenetics Unit, Institute of Human Genetics, and the Meirav High Risk Clinic, Chaim Sheba Medical Center, Tel-Hashomer, Israel.
Ephrat Levy-LahadThe Medical Genetics Institute and the NOGA High Risk Clinic, Shaare Zedek Medical Center, Affiliated with the Hebrew University School of Medicine, Jerusalem, Israel.
Noa Ephrat Ben BaruchThe Oncology Department, Kaplan Medical Center, Rehovot, Affiliated with the Hebrew University School of Medicine, Jerusalem, Israel.
Inbal KedarRabin Medical Center, Recanati Genetics Institute, Belinson Hospital, 4941492, Petah Tikvah, Israel.
D Gareth EvansManchester Centre for Genomic Medicine, Manchester University NHS Foundation Trust, Manchester, United Kingdom.
Sara HaimGenetics Institute, Shamir Medical Center, Zerifin, Affiliated to The Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Shani Paluch-ShimonDepartment of Oncology, Shaare Zedek Medical Center, Affiliated with the Hebrew University School of Medicine, Jerusalem, Israel.
Eitan FriedmanThe Oncogenetics Unit, Institute of Human Genetics, and the Meirav High Risk Clinic, Chaim Sheba Medical Center, Tel-Hashomer, Israel. eitan.friedman@sheba.health.gov.il.
Shaare Zedek Medical Center · ILTel Aviv University · ILKaplan Medical Center · ILRabin Medical Center · ILSheba Medical Center · ILManchester University NHS Foundation Trust · GB

Funding

Department of Health IS-BRC-1215–20007
6 · The paper itself

Abstract

Germline pathogenic sequence variants (PSVs) in BRCA1 substantially increase risk for developing breast (BC) and ovarian cancer (OvC). Yet, incomplete penetrance suggests that modifier factors affect phenotypic expression of mutant BRCA1 alleles. Analysis of identical BRCA1 PSV carriers of diverse ethnicities may provide further evidence for modifier factors. Female carriers of the 185delAG BRCA1 PSV identified through high-risk clinics in Israel, and Manchester England from 1998-2018 were eligible. Data were retrieved from patients records and confirmed (in Israel) by cross referencing with the Israeli National Cancer Registry. Overall, 2503 female carriers were included: 1715 (71.4%) Ashkenazi Jews (AJ), 201 (8.3%) Iraqi Jews and 383 (15.9%) of mixed ethnicity. In 102 (4.2%) cases ethnicity could not be ascertained. Of Israeli AJ carriers 649 (37.8%), 256 (14.9%) and 62 (3.6%) were diagnosed with BC, OvC or both cancers, respectively. For the Iraqi Jews these frequencies were 76 (37.8%), 43 (21.4%), and 8 (3.98%), respectively. Age at diagnosis of BC in AJ and Iraqi Jews was 46.7 ± 12.3 years and 52.8 ± 12.2 years, respectively (p = 0.001). For OvC age at diagnosis for AJ was 53.5 ± 10.7 years and for Iraqi Jews 50.1 ± 8.8 years (p = 0.0027). No differences in these parameters were noted between English Jews (n = 110) and non-Jews (n = 32). Age at diagnosis of BC and OvC differs between AJ and Iraqi Jews who carry an identical BRCA1 PSV. This finding supports the existence of modifier factors that may be ethnic specific.

Indexed as

Age FactorsBreast NeoplasmsGenes, BRCA1Germ-Line MutationHeterozygoteOvarian NeoplasmsAdultEnglandFemaleGenes, BRCA2HumansIraqIsraelJewsMiddle AgedAge at cancer diagnosisBRCA1 germline pathogenic sequence variantsIncomplete penetranceModifier factors

Identifiers

PMID33165727
OpenAlexW3106114613

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.